Skip to main content
. 2019 Apr 15;10(5):329. doi: 10.1038/s41419-019-1561-x

Fig. 5. AMPK phosphorylation inhibits SIRT1 activity.

Fig. 5

a, b Co-immunoprecipitation of AMPK with SIRT1 in A549 cells (**P < 0.01, using unpaired two-tailed Student’s t-test). c SIRT1 was immunoprecipitated and analyzed for threonine phosphorylation with AICAR (1 mM) or Compound C (20 μM) (*P < 0.05, **P < 0.01, using one-way ANOVA followed by Bonferroni’s multiple comparisons test). d The effect of GSNO on threonine phosphorylation of SIRT1 in sh-Control and sh-AMPK A549 cells (**P < 0.01; ns, not significant, using unpaired two-tailed Student’s t-test). e Co-immunoprecipitation of AMPK with SIRT1 with AICAR or Compound C (*P < 0.05, **P < 0.01, using one-way ANOVA followed by Bonferroni’s multiple comparisons test). f The activity of SIRT1 with AICAR or Compound C (**P < 0.01, using one-way ANOVA followed by Bonferroni’s multiple comparisons test). g The effect of GSNO on cell viability with Resveratrol (50 μM) or Suramin (50 μM) (**P < 0.01, using two-way ANOVA followed by Bonferroni’s multiple comparisons test). h Threonine phosphorylation of SIRT1 in SIRT1 WT and T344A mutants (**P < 0.01; ns, not significant, using one-way ANOVA followed by Bonferroni’s multiple comparisons test). i The activity of SIRT1 in SIRT1 WT and T344A mutants (***P < 0.001; ns, not significant, using one-way ANOVA followed by Bonferroni’s multiple comparisons test). The data are expressed as the mean ± SD of three independent experiments